PledPharma announces publication of case study in a scientific journal

Jan 12, 2009

Professor Per Jynge from Linköping University has together with scientists from the Radium Hospital in Oslo got a manuscript describing use of mangafodipir (PP-095) in a cancer treatment accepted for publication in Acta Oncologica

Preclinical research has shown that mangafodipir protects normal tissues without loss of antitumour activity during cytostatic treatment.

The manuscript describes how a patient with advanced colon cancer received 15 cycles of palliative cytostatic treatments with FOLFOX (levo-FOLinate, 5-Fluorouracil and Oxaliplatin). In 14 of these treatments the patient received pretreatment with PP-095. The case-report shows that the patient tolerated pretreatment with PP-095 well. After pretreatment with PP-095 no sign of serious FOLFOX-related toxicity (e.g., haematotoxicity or sensory neurtoxicity) was seen.

It should, however, be stressed that no conclusion can be drawn from PP-095 treatment in one single patient.

It will therefore be very exciting to receive results from the ongoing clinical study, says Assistant Professor Jan Olof G Karlsson, R&D responsible in PledPharma AB. Results from that study is expected in April 2009.

Accelerator Nordic AB has an active majority ownership position in a number of development companies within Bio Pharma and Medical Technology. The Accelerator group is addressing large growth markets as oncology, imaging and the orthopaedic market. The group has a business model based on licensing. Accelerator focuses on projects in the stage of verification where there is a clear unmet need and large industrial players. Accelerator Nordic AB is a publicly listed company traded on the Aktietorget exchange in Stockholm, Sweden.

For more information, please visit, www.acceleratorab.se

PledPharma AB develops new pharmaceutical applications based on a clinically approved PLED-derivative, PP-095, with an initial candidate for oncology that already has entered Clinical Phase II trials. PledPharma’s core technology is an omnipotent catalytic antioxidant that has characteristics that protect healthy cells during cancer treatment with chemotherapy and/or radiation. When used as an adjunct treatment, it has the potential to improve both clinical outcomes and patient well-being. In addition to cancer treatment, catalytic antioxidants have a wide range of potential indications, e.g., myocardial infarction, stroke and neurodegenerative diseases.

For more information, please visit www.pledpharma.se